Cipla to sell 51 percent stake in Uganda arm for USD 25-30 million

Written by Ruchika Sharma Published On 2023-03-15T16:00:19+05:30 | Updated On 15 March 2023 4:00 PM IST

USFDA issues 2 observattions for Cipla arm Mahape facility

Mumbai: Pharma major Cipla Limited and its wholly owned subsidiaries, Cipla (EU) Limited, UK and Meditab Holdings Limited, Mauritius, have entered into a Share Purchase Agreement with Africa Capitalworks SSA 3 for the sale of 51.18 percent stake in Cipla Quality Chemical Industries Limited (CQCIL), Uganda. Subsequent to the sale, CQCIL will cease to be a subsidiary of Cipla.

"Consideration to be received by Cipla (EU) Limited and Meditab Holdings Limited shall be in the range of USD 25-30 million which shall be subject to annualised audited EBITDA of CQCIL for FY23 and other adjustments as agreed between the parties and stated in the Share Purchase Agreement," the company stated in a recent BSE filing.

The proposed sale is expected to be completed by 31st May 2023, subject to obtaining regulatory approvals and completion of conditions precedent as mutually agreed between the parties.

The buyer, Africa Capitalworks SSA 3, is a wholly owned subsidiary of Africa Capitalworks Holdings (“ACW”), an investment management company incorporated in Mauritius. ACW is engaged in providing permanent equity capital and complementary skills to mid‐market companies across Sub‐Saharan Africa.

Read also: CDSCO Panel allows Cipla to waive requirements for phase 4 study of tocilizumab inj for giant cell arthritis

Cipla Limited is an Indian multinational pharmaceutical and biotechnology company, headquartered in Mumbai, India. The Company was founded by Khwaja Abdul Hamied in 1935 in Mumbai.

The company specializes in the respiratory, anti-retroviral, urology, cardiology, anti-infective and CNS segments. Cipla's 47 manufacturing sites around the world produce 50+ dosage forms and 1,500+ products using cutting-edge technology platforms to cater to 86 markets.

Read also: Cipla expects elevated capital expenditure on automation to continue for three more years

ciplacipla newsMeditab HoldingsAfrica CapitalworksCipla Quality Chemical Industries

Ruchika Sharma

Ruchika Sharma joined Medical Dialogue as an Correspondent for the Business Section in 2019. She covers all the updates in the Pharmaceutical field, Policy, Insurance, Business Healthcare, Medical News, Health News, Pharma News, Healthcare and Investment. She has completed her B.Com from Delhi University and then pursued postgraduation in M.Com. She can be contacted at editorial@medicaldialogues.in Contact no. 011-43720751